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esiritide Administration
n Patients With Left
entricular Dysfunction
ndergoing Coronary
rtery Bypass Surgery*
srael Belenkie, MD, FACC
algary, Alberta, Canada
esiritide has the same amino acid sequence as human
-type natriuretic peptide (BNP), which is secreted by the
entricles in response to myocardial stretch. B-type natri-
retic peptide relaxes vascular smooth muscle and causes
rterial dilatation (1–7). Although BNP may also cause
enodilation, the fact that it does not reduce right-sided
ressures in precapillary pulmonary hypertension suggests
hat it may be only a weak venodilator (8,9). B-type
atriuretic peptide promotes sodium and water excretion
1–3,10). The filtration fraction and glomerular filtration
ate increase consistent with vasoconstriction of efferent
rterials and vasodilation of afferent arterials. Sodium reab-
orption is inhibited in both proximal and distal tubules.
ssociated changes include decreased stimulation of the
enin angiotensin and sympathetic nervous systems and
ecreased plasma aldosterone and endothelin-1 levels
4,11,12). Whether these changes are related to the hemo-
ynamic effects of BNP or are direct effects is uncertain.
See page 716
As with other vasodilators, nesiritide is effective in treat-
ng acute decompensated congestive heart failure. In addi-
ion to symptomatic improvement, filling pressures and
ulmonary vascular resistance are reduced and cardiac out-
ut is increased in a dose-dependent manner without an
ncreased heart rate or plasma norepinephrine level (4).
here is no apparent tachyphylaxis during infusions up to
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the Department of Cardiac Sciences and the Libin Cardiovascular Institute,
niversity of Calgary, Calgary, Alberta, Canada. Dr. Belenkie has acted as an adviser
o Ortho-Biotech, a subsidiary of Johnson & Johnson responsible for nesiritide in3
anada, and has submitted a grant proposal to Ortho-Biotech to fund a study with
esiritide.8 h. Nesiritide was shown to be at least as effective as
itroglycerin in treating acute decompensated heart failure
5). However, a meta-analysis suggesting that long-term
utcomes may be worse in patients treated with BNP (13)
as created considerable controversy that remains to be
esolved.
As reported by Mentzer et al. (14) in this issue of the
ournal, the NAPA (Nesiritide Administered Peri-
nesthesia in Patients Undergoing Cardiac Surgery) trial
as a placebo-controlled randomized study in which pa-
ients with left ventricular dysfunction (ejection fraction
40%) undergoing bypass surgery were administered ne-
iritide (low dose and no bolus) or placebo after induction of
nesthesia for 24 to 96 h in addition to usual care. The focus
as primarily on the effects of nesiritide on renal function.
atients were screened to ensure that blood pressure and
lling pressures were not too low for them to safely receive
n arterial dilator. The rationale was based on the associa-
ion of renal dysfunction and worse outcomes after bypass
urgery—improved renal protection might improve out-
omes. Although serum creatinine increased in both groups,
t returned to baseline within 12 h in those treated with
esiritide and remained elevated in the placebo group
hroughout hospitalization. There was better preservation of
he glomerular filtration rate, and urine output was greater
n those who received nesiritide. Renal protection was
reatest in patients with preexisting renal dysfunction.
ospital length of stay was shorter, and mortality up to 180
ays may have been lower in the treatment group.
The effects of nesiritide on renal function were clear;
owever, translation of those results to clinical outcomes
emains to be demonstrated. Mortality was not a prespeci-
ed end point but was added during the course of the trial
nd, even more importantly, data collection was incomplete.
here were few deaths, so the lack of follow-up in a
ubstantial proportion of the patients precludes acceptance
f the mortality difference with confidence despite the
tatistical significance of the results. Concomitant drug use
ould be of great interest. If nesiritide administration can
educe dependence on inotropic agents and diuretics to
chieve similar or better hemodynamics in addition to renal
rotection, this would support considering its use. The
echanism of renal protection was unclear in the NAPA
rial—hemodynamic results were similar in both groups. A
irect renal protective effect is a viable but unproven
ypothesis. Perhaps inotropes and vasoconstrictors may
rovide seemingly good acute responses but with negative
ownstream effects, as has been suggested in acute decom-
ensated heart failure (15,16), but incomplete documenta-
ion of their use is a missed opportunity to test that
ypothesis. Vasoactive agents, diuretics, and inotropes were
isted, but the details, including doses, were such that no
onclusion can be offered regarding the effects of nesiritide
n concomitant drug use. It is also important to note that
03 patients were randomized in 54 participating centers
o
r
c
v
t
p
A
a
f
o
c
p
p
O
n
w
m
g
o
s
a
o
i
f
H
u
a
f
r
R
H
A
R
1
1
1
1
1
1
1
1
1
1
2
2
728 Belenkie JACC Vol. 49, No. 6, 2007
Editorial Comment February 13, 2007:727–8ver 15 months; therefore, the general applicability of the
esults in consecutive study-eligible patients is uncertain.
As stated by the authors, the NAPA trial should be
onsidered exploratory. The results in patients with left
entricular dysfunction undergoing bypass surgery support
he need for further study of nesiritide in this patient
opulation, as well as in others with congestive heart failure.
t this time, it remains unclear just where nesiritide best fits
mong agents available for parenteral treatment of heart
ailure. It is also important to assess the venodilating effects
f nesiritide. If it is only effective as an arterial dilator,
ombined use with nitroglycerin may be appropriate in some
atients, particularly in those with relatively low blood
ressure in whom hypotension should be avoided (17–19).
ptimal dosing, including whether a bolus should be used,
eeds clarification. Low doses may improve renal function
hen blood pressure is maintained, whereas higher doses
ay cause hypotension and decrease renal perfusion, exag-
erated by concomitant diuretic use (20). Experience with
ther parenteral vasodilators would suggest that doses
hould be titrated to desired effects rather than using
rbitrary doses.
Although recent meta-analyses cause concern regarding
utcomes, including worsening renal function with nesirit-
de in acute decompensated heart failure (13,21), results
rom ongoing clinical trials will soon address these issues.
owever, there is still much to learn regarding how best to
se this promising agent. The NAPA trial provides encour-
ging results in one subgroup of patients who might benefit
rom the use of nesiritide, but more comprehensive data are
equired before promoting routine use in this population.
eprint requests and correspondence: Dr. Israel Belenkie,
ealth Sciences Centre, 3330 Hospital Drive NW, Calgary,
lberta, Canada T2N 4N1. E-mail: belenkie@ucalgary.ca.
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